Sagimet Biosciences Inc.
SGMT
$2.21
$0.199.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -63.46% | -39.36% | -4.34% | 1.53% | 8.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.85% | -9.02% | 69.55% | 129.36% | 183.45% |
| Change in Net Operating Assets | -7.16% | -206.70% | 221.99% | 115.06% | -123.21% |
| Cash from Operations | -78.55% | -59.49% | 13.92% | 14.94% | 2.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -590.33% | -342.20% | -320.43% | 69.71% | 139.30% |
| Cash from Investing | -590.33% | -342.20% | -320.43% | 69.71% | 139.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18.04% | 26.94% | -- | -- | 747,275.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.30% | -8,196.36% | -219.44% | -1,890.95% | -4,038.82% |
| Cash from Financing | 21.65% | 21.72% | 17,541.60% | 86,592.76% | 118,136.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.07% | -124.92% | 451.49% | 513.79% | 232.54% |